Long-term efficacy, safety, and patient-reported outcomes of oveporexton in adults with narcolepsy type 1
Oveporexton, a selective oral orexin-2 receptor agonist, represents a targeted therapeutic approach for narcolepsy type 1 (NT1). Phase 2 and 3 trials demonstrate significant improvements in wakefulness, excessive daytime sleepiness, and cataplexy, alongside potential cognitive benefits. However, available data are limi...